Advertisement

Current Cardiology Reports

, 20:140 | Cite as

Refractory In-Stent Restenosis: Improving Outcomes by Standardizing Our Approach

  • Ron Waksman
  • Micaela Iantorno
Interventional Cardiology (SR Bailey, Section Editor)
  • 64 Downloads
Part of the following topical collections:
  1. Topical Collection on Interventional Cardiology

Abstract

Purpose of Review

This review will focus on our approach for the treatment of refractory in-stent restenosis.

Recent Findings

The discovery of bare metal stents over three decades ago set a milestone in the evolution of percutaneous coronary intervention, which is currently the most widely performed procedure for the treatment of symptomatic coronary disease. However, the broad utilization of stents resulted in the new phenomenon of in-stent restenosis (ISR). Over the years, there has been an increase of the incidence of ISR despite continued improvement of drug-eluting stent (DES) technology. The mechanism of ISR is multifactorial, including biological, mechanical, patient, and operator-related factors. The most common factor is aggressive neointimal proliferation and neoatherosclerosis. ISR presentation is not benign, and treatment is challenging, especially in cases of DES-ISR.

Summary

We review available therapy modalities for ISR, including medical therapy, scoring balloons, atheroablative therapies, repeat DES, vascular brachytherapy, drug-coated balloons, and coronary artery bypass grafting.

Keywords

In-stent restenosis Bare metal stent Drug-eluting stents Balloon angioplasty Drug-coated balloon 

Notes

Compliance with Ethical Standards

Conflict of Interest

Ron Waksman: Advisory Board: Abbott Vascular, Amgen, Boston Scientific, Medtronic, Philips Volcano, Pi-Cardia Ltd., Cardioset. Consultant: Abbott Vascular, Amgen, Biosensors, Biotronik, Boston Scientific, Medtronic, Philips Volcano, Pi-Cardia Ltd., Cardioset; Grant Support: Abbott Vascular, AstraZeneca, Biosensors, Biotronik, Boston Scientific, Chiesi. Speakers Bureau: AstraZeneca, Chiesi; Investor: MedAlliance.

Micaela Iantorno has no conflicts to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–907.CrossRefGoogle Scholar
  2. 2.
    Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation. 1993;88(3):1310–23.CrossRefGoogle Scholar
  3. 3.
    Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872–8.CrossRefGoogle Scholar
  4. 4.
    Alfonso F, Cequier A, Angel J, Marti V, Zueco J, Bethencourt A, Mantilla R, Lopez-Minguez JR, Gomez-Recio M, Moris C and others. Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis. Insights from the Restenosis Intra-stent Balloon angioplasty versus elective stenting (RIBS) randomized trial. Am Heart J 2006;151(3):681.e1–681.e9.CrossRefGoogle Scholar
  5. 5.
    Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. and others. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937–48.CrossRefGoogle Scholar
  6. 6.
    Byrne RA, Sarafoff N, Kastrati A, Schomig A. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf. 2009;32(9):749–70.CrossRefGoogle Scholar
  7. 7.
    Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. and others. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315–23.CrossRefGoogle Scholar
  8. 8.
    Piccolo R, Stefanini GG, Franzone A, Spitzer E, Blochlinger S, Heg D, Juni P, Windecker S. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis. Circ Cardiovasc Interv 2015;8(4).Google Scholar
  9. 9.
    Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004;110(10):1226–30.CrossRefGoogle Scholar
  10. 10.
    Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30(6):1428–36.CrossRefGoogle Scholar
  11. 11.
    Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A. 2003;100(8):4754–9.CrossRefGoogle Scholar
  12. 12.
    Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart. 2003;89(2):218–24.CrossRefGoogle Scholar
  13. 13.
    Tsigkas GG, Karantalis V, Hahalis G, Alexopoulos D. Stent restenosis, pathophysiology and treatment options: a 2010 update. Hell J Cardiol. 2011;52(2):149–57.Google Scholar
  14. 14.
    Alfonso F, Perez-Vizcayno MJ, Cruz A, Garcia J, Jimenez-Quevedo P, Escaned J, Hernandez R. Treatment of patients with in-stent restenosis. EuroIntervention 2009;5 Suppl D:D70–8.Google Scholar
  15. 15.
    Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER investigators. Circulation. 1999;100(8):799–806.CrossRefGoogle Scholar
  16. 16.
    Macander PJ, Roubin GS, Agrawal SK, Cannon AD, Dean LS, Baxley WA. Balloon angioplasty for treatment of in-stent restenosis: feasibility, safety, and efficacy. Catheter Cardiovasc Diagn. 1994;32(2):125–31.CrossRefGoogle Scholar
  17. 17.
    Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63(24):2659–73.CrossRefGoogle Scholar
  18. 18.
    Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. Jama. 2005;293(2):165–71.CrossRefGoogle Scholar
  19. 19.
    Alfonso F, Perez-Vizcayno MJ, Hernandez R, Goicolea J, Fernandez-Ortiz A, Escaned J, et al. Long-term outcome and determinants of event-free survival in patients treated with balloon angioplasty for in-stent restenosis. Am J Cardiol. 1999;83(8):1268–70 a9.CrossRefGoogle Scholar
  20. 20.
    Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, et al. and others. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344(4):250–6.CrossRefGoogle Scholar
  21. 21.
    Waksman R, White RL, Chan RC, Bass BG, Geirlach L, Mintz GS, et al. and others. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation. 2000;101(18):2165–71.CrossRefGoogle Scholar
  22. 22.
    Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, et al. and others. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997;336(24):1697–703.CrossRefGoogle Scholar
  23. 23.
    Sharma SK, Kini A, Mehran R, Lansky A, Kobayashi Y, Marmur JD. Randomized trial of rotational atherectomy versus balloon angioplasty for diffuse in-stent restenosis (ROSTER). Am Heart J. 2004;147(1):16–22.CrossRefGoogle Scholar
  24. 24.
    vom Dahl J, Dietz U, Haager PK, Silber S, Niccoli L, Buettner HJ, et al. and others. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). Circulation. 2002;105(5):583–8.CrossRefGoogle Scholar
  25. 25.
    Mehran R, Dangas G, Mintz GS, Waksman R, Abizaid A, Satler LF, et al. and others. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. Circulation. 2000;101(21):2484–9.CrossRefGoogle Scholar
  26. 26.
    Holmes DR Jr, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, et al. and others. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. Jama. 2006;295(11):1264–73.CrossRefGoogle Scholar
  27. 27.
    Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, et al. and others. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. Jama. 2006;295(11):1253–63.CrossRefGoogle Scholar
  28. 28.
    • Byrne RA, Cassese S, Windisch T, King LA, Joner M, Tada T, et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. EuroIntervention. 2013;9(7):797–802 Pooled analysis of the ISAR DESIRE and ISAR DESIRE 2 showing that the efficacy of sirolimus-eluting but not paclitaxel-eluting stents is significantly reduced when used for treatment of SES restenosis as compared to bare metal stent restenosis indicating a possible role for drug resistance in restenosis within these stents. CrossRefGoogle Scholar
  29. 29.
    •• Alfonso F, Perez-Vizcayno MJ, Garcia Del Blanco B, Garcia-Touchard A, Lopez-Minguez JR, Masotti M, Zueco J, Melgares R, Mainar V, Moreno R and others. Everolimus-eluting stents in patients with bare-metal and drug-eluting in-stent restenosis: results from a patient-level pooled analysis of the RIBS IV and V trials. Circ Cardiovasc Interv 2016;9(7). Pooled data analysis from ISAR-DESIRE and ISAR-DESIRE 2 that showed lower antirestonitc efficacy followin SES reimplantation supporting a role for drug resistance in stent restonsis This patient-level pooled analysis of the RIBS IV and RIBS V randomized clinical trials suggests that EES provide favorable outcomes in patients with ISR. However, the results of EES are less satisfactory in patients with DES-ISR than in those with bare-metal stent ISR. Google Scholar
  30. 30.
    Waksman R, Steinvil A. In-stent restenosis?, The Raiders of the Magic Remedy. Circ Cardiovasc Interv. 2016;9(7).Google Scholar
  31. 31.
    Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Perez-Vizcayno MJ, et al. and others. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386(9994):655–64.CrossRefGoogle Scholar
  32. 32.
    Giacoppo D, Gargiulo G, Aruta P, Capranzano P, Tamburino C, Capodanno D. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. Bmj. 2015;351:h5392.CrossRefGoogle Scholar
  33. 33.
    Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. and others. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). J Am Coll Cardiol. 2006;47(1):e1–121.CrossRefGoogle Scholar
  34. 34.
    Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355(20):2113–24.CrossRefGoogle Scholar
  35. 35.
    Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al. and others.Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381(9865):461–7.CrossRefGoogle Scholar
  36. 36.
    Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia Del Blanco B, Seidelberger B, Iniguez A, et al. and others. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V clinical trial (restenosis intra-stent of bare metal stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014;63(14):1378–86.CrossRefGoogle Scholar
  37. 37.
    Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia del Blanco B, Garcia-Touchard A, Lopez-Minguez JR, et al. and others. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. J Am Coll Cardiol. 2015;66(1):23–33.CrossRefGoogle Scholar
  38. 38.
    Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, et al. and others. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. JACC Cardiovasc Interv. 2015;8(3):382–94.CrossRefGoogle Scholar
  39. 39.
    Alfonso F, Perez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, Garcia-Touchard A, et al. and others. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [restenosis intra-stent: balloon angioplasty versus drug-eluting stent]). JACC Cardiovasc Interv. 2012;5(7):728–37.CrossRefGoogle Scholar
  40. 40.
    Alfonso F, Auge JM, Zueco J, Bethencourt A, Lopez-Minguez JR, Hernandez JM, et al. and others.Long-term results (three to five years) of the restenosis intrastent: balloon angioplasty versus elective stenting (RIBS) randomized study. J Am Coll Cardiol. 2005;46(5):756–60.CrossRefGoogle Scholar
  41. 41.
    Mehran R, Dangas G, Abizaid A, Lansky AJ, Mintz GS, Pichard AD, et al. and others. Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: short- and long-term results. Am Heart J. 2001;141(4):610–4.CrossRefGoogle Scholar
  42. 42.
    Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. and others. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–122.CrossRefGoogle Scholar
  43. 43.
    Alraies MC, Darmoch F, Tummala R, Waksman R. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol. 2017;9(8):640–51.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Section of Interventional CardiologyMedStar Washington Hospital CenterWashingtonUSA

Personalised recommendations